Additional Information
Market: AIM
Sector: Pharmaceuticals & Biotechnology
EPIC: EAH
Latest Price: 224.00p  (0,00%)
52-week High: 260.00p
52-week Low: 186.50p
Market Cap: 123.36M
1 year chart
1 day chart
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Eco Animal Health Group Plc
www.ecoanimalhealthgroupplc.com

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for global animal health markets. Our products for these growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

Pdf

ECO Animal Health Group’s Chinese Aivlosin factory gets US FDA approval

26th Jul 2010, 7:39 am ECO Animal Health Group’s Chinese Aivlosin factory gets US FDA approval

ECO Animal Health Group (LON:EAH) told investors that its Chinese manufacturing facility has been approved by the US Federal Drug Administration (FDA), following a successful Good Manufacturing Practice (GMP) inspection.

The facility manufactures the Aivlosin active pharmaceutical ingredient.

The company said the approval marks a very important milestone in the development and registration programme for Aivlosin in the USA.

The facility has already been approved by EU and Japanese regulatory authorities.

ECO Animal Health Group develops, registers and markets pharmaceutical products for global animal health markets. Its products for these growth markets promote well-being in animals and include the novel macrolide antibiotic, Aivlosin, as well as a range of generic therapeutic products.

Aivlosin targets a wide range of diseases spanning from enzootic pneumonia to swine dysentery. The drug has been approved for use in pigs and poultry in Europe, South Africa, Japan, Asia and South America with ECO expecting it to receive approvals soon for use in pigs in the United States.

The group’s other products include Chlortet, which is aimed at controlling E.coli infections, and performance promoters such as Flaveco, designed to improve efficiency and growth in pigs.

ECO also announced that its full-year results, for the year ended 31 March 2010, will be published on 10 August 2010.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.